Summary
Dehydrated Alcohol has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Peripheral Neuropathy (Diabetic Peripheral Neuropathy) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Peripheral Neuropathy (Diabetic Peripheral Neuropathy). ClinicalTrials.gov lists 8 registered trials linking Dehydrated Alcohol to Peripheral Neuropathy (Diabetic Peripheral Neuropathy): 2 are currently recruiting; 6 have completed. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 270 participants. Registration activity spans 2014 to 2026. No published literature item is linked to Dehydrated Alcohol and Peripheral Neuropathy (Diabetic Peripheral Neuropathy) in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Diabetic Neuropathy ranks 186 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Progressive with worsening glycaemic control; reversal essentially not possible with current treatments once established; spontaneous improvement only in cases of rapid glycaemic normalisation early in course.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 41.0 (trials 21.0, literature 0.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 2 recruiting, 0 active / not yet recruiting, 6 completed, 0 other |
| Linked publications | 0 |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | DGIdb |
| Linked via biomarker / target | CACNA1C |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT02728687 | Topical Menthol +/- Mannitol for Painful Diabetic Peripheral Neuropathy 2017 | completed | PHASE1, PHASE2 | 72 |
| NCT02169167 | Comparison of Resin Salve and Octenidine in Patients With Neuropathic Diabetic Foot Ulcers 2014 | completed | Not applicable | 35 |
| NCT06579716 | Whole-Body Vibration Versus Kineso Tape on Nerve Conduction in Patient With Diabetic Peripheral Neuropathy 2022 | completed | Not applicable | 60 |
| NCT04154046 | Treatment of Impending Ulcers Associated With Hammer, Mallet and Claw Toe Deformities in the Diabetic Patient Setting 2019 | completed | Not applicable | 80 |
| NCT02107469 | A Study of Phyllanthus Niruri and Sida Cordifolia in Diabetic Peripheral Polyneuropathy 2014 | completed | Not applicable | 98 |
| NCT07078058 | Low Level Laser VS Transcutaneous Vagus Nerve Stimulation on Vascular Changes in Patients With Diabetic Polyneuropathy 2025 | completed | Not applicable | 30 |
| NCT07405021 | Effect of Vagus Nerve Stimulation on Pain Intensity, Nerve Conduction Studies and Functional Outcomes in Diabetic Peripheral Neuropathy Patients 2026 | recruiting | Not applicable | 40 |
| NCT07223268 | Comprehensive Assistance and Resources for Effective Diabetic Foot Navigation 2025 | recruiting | Not applicable | 270 |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target CACNA1C. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Dehydrated Alcohol approved for Peripheral Neuropathy (Diabetic Peripheral Neuropathy)?
Dehydrated Alcohol has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Peripheral Neuropathy (Diabetic Peripheral Neuropathy) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Peripheral Neuropathy (Diabetic Peripheral Neuropathy). Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Dehydrated Alcohol in clinical trials for Peripheral Neuropathy (Diabetic Peripheral Neuropathy)?
ClinicalTrials.gov lists 8 registered trials linking Dehydrated Alcohol to Peripheral Neuropathy (Diabetic Peripheral Neuropathy): 2 are currently recruiting; 6 have completed. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 270 participants. Registration activity spans 2014 to 2026.
What does the evidence show for Dehydrated Alcohol in Peripheral Neuropathy (Diabetic Peripheral Neuropathy)?
Dehydrated Alcohol has 6 completed registered trials for Peripheral Neuropathy (Diabetic Peripheral Neuropathy) but no linked publication, which usually means results are unpublished, pending, or not yet matched to this record. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target CACNA1C. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.